Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > We should at least be at .45 yes .
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(74)
•••
Comment by consultant99on Nov 30, 2021 10:26pm
588 Views
Post# 34183342

RE:RE:RE:RE:RE:RE:RE:RE:RE:We should at least be at .45 yes .

RE:RE:RE:RE:RE:RE:RE:RE:RE:We should at least be at .45 yes .The simple answer as to why the share price languishes is messaging in my opinion.

The information being provided is far too technical for the average investor and the company doesn't provide any meaningful interpretation. 

Perhaps for the first time in quite a while management actually seemed to be optimistic on the potential success rate. Let's face it - if management is excited about the trial how do you interest new investors?

If I was to ask management a question it would be along the lines of "if the results continue along current success levels how do you see BTD unfolding and it's impact on the company"?

I believe that once investors know the prize and when it is most likely to be earned the share price will begin to rise as the risk declines.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities